Antimicrobial resistance patterns and their encoding genes among Acinetobacter baumannii strains isolated from burned patients by Asadollahi, P. et al.
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, August 2014. Vol. 11(2), 523-529
* To whom all correspondence should be addressed.
Tel.:+989166438900;
E-mail: a.nasseri27@gmail.com
Using Phage as A Highly Specific Antibiotic Alternative Against 
Methicillin Resistance Staphylococcus aureus (MRSA)
Fatemeh Rezaei1, Ahmad Nasser2*, Farid Azizi Jalilian5, 
Zack Hobbs3 and Reza Azizian2,4
1Department of Virology, TarbiatModares University, Tehran, Iran.
2Student Research Committee, Ilam University of Medical Sciences, Ilam, Iran.
3The Evergreen State College, Olympia, Washington, USA.
4Research & Developing Center, Mahan Gene Pajoh (Poyesh),Tehran, Iran. 
5Department of Microbiology, Ilam University of Medical Science, Ilam, Iran.
doi: http://dx.doi.org/10.13005/bbra/1302
(Received: 28 June 2014; accepted: 02 August 2014)
 Misuse of antibiotics in humans and animals often leads to the development 
ofmultidrug resistance (MDR)bacteria. Resistance can occur within a few years of novel 
antibiotics being introduced. Lytic bacteriophage (phage) are a kind of virus that undergo a 
cyclical lifestyle wherein they infect and replicate through the use of a bacterial host cell and 
cause cell lysis. Phage recognizes specific receptors on their host cell to attach to,insert their 
DNA and take over their host’s molecular machinery. These receptors only exist on the surface 
of specific bacterial host cells and are often not present on other non-specific bacteria and not 
especially on the surfaces of eukaryotic cells. The mechanisms by which phage can destroy 
bacteria are different from antibiotics; phage can lyse MDR resistant bacteria without being 
affected by hydrolytic enzymes or ribosomal variations that’s mean unlike drug resistance 
mechanism which bacteria can destroy the drug before can inter the bacteria cell, the phage 
not effected with such enzyme.
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 Bacteriophages (phages) are viruses that 
insert their genomes into bacterial cells, rapidly 
taking control of the host’s molecular machinery 
and produce progeny that are released by lysis 
of the bacterium. Phage therapy involves using 
phages as a treatment or prophylaxis application 
against infectious diseases caused by bacteria.
The worldwide prevalence, persistence and 
incurabilityof pathogenic multidrug resistant 
bacteria is a serious public health concern that 
will bring about the post-antibiotic era. This result 
is primarily from the extensive use of antibiotics 
that puts selective pressure on bacteria to develop 
mechanisms of resistance1. Phage were first 
discovered separately by Fredrick Twort and Félix 
d’Herelle in the early 20th century and later used 
heavily among Eastern Europe countries and the 
form Soviet Unionfor treating and preventing 
bacterial infectious diseases[2-4].In more recent 
years an interest in phage therapy has been 
resurrected as a potential option to deal with MDR 
bacteria infections.
MRSA
 Staphylococci are gram-positive bacteria 
that cause various infectious diseasesin humans 
and animals.Staphylococci are classified using 
different methods, one of the main categories on 
the basis of coagulase.Coagulase is a major factor 
that causes blood clotting in the proximity of 
the bacteria and bacteria lacking in these factors 
often make poor pathogens.Accordingly, the 
only specie of Coagulase-positive Staphylococci 
in this category is S. aureus.S. aureus initially 
was susceptible to Penicillin, but with time and 
indiscriminate use of antibiotics, resistant strains 
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emerged along with ones that became resistant to 
more recent generations of β-lactam antibiotics. 
Methicillin was among the later generation drugs 
and became commonly used after the emergence 
ofPenicillin-resistant S. aureus5,6.Two subsets of 
S.aureus strains are further distinguished based on 
resistance and susceptibility to Methicillin; MRSA 
(Methicillin Resistance Staphylococcus aureus), 
and MSSA (Methicillin Sensitive Staphylococcus 
aureus) (Fig. 1).
 Diseases caused by S. aureus include 
endocarditis, wound infection, carbuncle, toxic 
shock syndrome, osteomyelitis, etc.These bacteria 
produce a toxin that damage cells as well as being 
able to directly attack the cell to cause apoptosis 
using a Fibronectin Binding Protein7.Drug 
resistance in MRSA isthe result of a mecA gene 
that produces Penicillin-Binding Protein (PBP)
witha lower affinity8. The PBP is a peptidogly 
cansynthesis protein and involved in the synthesis 
of peptidoglycan, which is the major component 
of bacterial cell walls.
Phage 
 Nearly 108 phage particles per ml 
are present in the oceans and an estimated 
1030 phage particles exist in the world.Phages 
can be divided based on features such as host 
range, absence or presence of an lipid envelope, 
physical characteristics (size and morphology 
of capsid and tails, if present), resistance to 
organic solvents, genome composition (single or 
double-stranded DNA or RNA) and if they have 
antigenic properties9,10. Based on classification 
by the International Committee of Taxonomy of 
Viruses (ICTV) a vast majority of phages are in 
a one category called Caudovirales9, have one 
of three tail morphologies and ads DNA genome 
packaged a head-full into their capsid11.Phages 
are further divided into three types based on 
their life cycle: lysogenic, lytic and chronic12.The 
genome of a temperate phage, once inserted into 
the bacterial cytoplasm, integratesinto the host 
chromosome and can undergo a dormant state, 
even be replicated along with the host chromosome 
during binary fission and at a later time excise from 
the chromosome to form phage particles and utilize 
the lytic cycle13. Obligatorily lytic phages however 
inject their genome into the cytoplasm of the 
bacteria, hijack the cell and immediately convert 
it into producing progeny and shorty (or eventually 
a few hours later which is the case with T4-like 
phages due to lysis inhibition) releases them by 
destroying the bacteria through lysis. Chronic 
phage can replicate and release their progeny from 
the host without compromising the viability of their 
host.Phages can survive outside the host cell but 
utilization of the host is requiredfor replication14. 
Phage specificity can be used to further characterize 
bacterial strains through a method called phage 
typing15, 16.
 There are several problems to identifying 
phagesone of which is that phages cannot be 
cultured outside of ahost17.Phage particleswill 
be comprised of a tail, a filamentous tube or 
polymorphous structure11.The composition of a 
Caudioviridae includes acapsid, disk plates that 
make a tail sheath, a base plate and aspike for 
Siphoviridae or multiple tail fibers for Podo- and 
Myoviridae. In addition to phage therapy, phage 
can be used for industrial purposes, including 
phage display, detection of pathogenic bacteria 
via luminescence18, provide bactericidal endolysin 
proteins that clear if not mitigate the prevalence 
of pathogens from food products20, enhanced 
food safety applications in agricultural and aqua 
culture settings, as a prophylactic and in hospitals 
to control biofilm-forming pathogens and common 
bacterial infections associated with hospital visits19.
Advantages of phage therapy
 (A) Effective against MDR bacteria 
because they use significantly different mechanisms 
in comparison to antibiotics; (B) Phages are 
capable of evolving/mutating therefore, they can 
respond to phage-resistant bacteria; (C) Shifting of 
target organisms does not occur because it has high 
specificity and secondary infections are avoided21; 
(D) Phages ortheir protein products, such holin 
and lysozyme,do not negatively affect eukaryotic 
cells22, 23;(E) Phages can replicated at the site of a 
bacterial infection; (F)Phage-resistant bacteria are 
likely susceptible to other phages24.
Classification of phage and infection mechanism:
 Phages are classified into 13 families 
according to nucleic acid type, morphology and the 
presence or absence of an envelope or lipid layer22. 
Most phages have a tail and are further classified 
into three families according to the morphological 
features of a tail: Myoviridae (a contractile tail most 
commonly found in T-even phages), Siphoviridae 
(long, flexible, non-contractile tail seen in T5) and 
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Podoviridae (extremely short tail; e.g., T7)25,26. 
Phage infections function much like other viruses 
wherein the ûrst step is to make contact with a 
receptor, usually a protein or sugar component on 
the bacterial surface. Phages are able to absorb 
to speciûc bacterial species and even to specific 
strains within a species; or genera within the same 
gram type which are called polyvalent phages27.
The second step (for lytic phages specifically) is 
the injection of DNA into the bacterial cytoplasm, 
use the host RNA polymerase to express early 
mode genes from the phage genome, take over 
of the host by either degrading the host genome 
or ejecting it from the cell,replicate the phage 
genome, and synthesized multiple middle and late 
genes that encode proteins such as the capsid and 
tail, followed by the genomic DNA being packaged 
into the capsid, resulting in completed phage. In the 
last step, phages produce the endolysin that destroy 
the peptidoglycan of the cell wall allowing phage 
progeny to be released28.
Table 1. Phage therapy: Pros and Cons
Researcher(s) Title Year Result  
Bruynoghe R. and Essai de thérapeutique 1921 Phage treated Staphylococcal   
Maisin J.  aumoyen du   skin disease by injecting the   
 bacteriophage  phage near the site of the infection. 
Smith, H. W., and Successful treatment of 1982 Successful treatment of E. col  
Huggins M. B.  experimental Escherichia coli   i infections in mice without  
 infections in mice using    collateral damage.   
 phages: its general 
 superiorityover antibiotics
Smith, H. W., and  Effectiveness of phages 1983 Used single doses of specific   
M.B. Huggins.   in treating experimental   phage to treat diarrhealE.coli   
 E. coli diarrhea in calves,   strains, reduced and/or stopped  
 piglets and lambs   the diarrhea.  
S ´Lopek S. et al Results of 1981–1986 Phage were used to treat 518   
 bacteriophage  patients with antibiotic   
 treatment of  resistant bacterial infections;   
 suppurative bacterial infections   the success rate of curing 
 in the years   patientswas between 75–100%. 
Bogovazova, G. G.,  Immunobiological  1992 Demonstrated their phagesto   
et al. properties and therapeutic   besafe and effective   
 effectiveness of  against treating invivo Klebsiella 
 preparations from Klebsiella    infections.  
 bacteriophages    
Soothill, J. S. et al. Bacteriophage prevents 1994 Phage used as a bio-control   
 destruction of skin grafts   against P.aeruginosa infections.
 by Pseudomona s aeruginosa   
Thiel K. Old dogma, new tricks 2004 Demonstrated how therapeutic  
 21st Century phage therapy  phages can be produced 
   inexpensively
Gill J. J. et al. Efficacy and Pharmacokinetics  2006 This study showedthe ability  
 of Bacteriophage Therapy  of adaily dose of lytic staph
 in Treatment of Subclinical   phage K to eliminate bovine S  
 Staphylococcus aureus  aureusintra- mammary 
 Mastitis in Lactating Dairy Cattle  infections during lactation in24 
   cows. 
Trigo G. et al. Phage Therapy is Effective against 2013 Mycobacteriophage D29was   
 Infection by Mycobacterium ulcerans  evaluated for therapeutic   
 in a Murine Footpad Model  efficacy in footpad mice
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Fig. 1. Differentiation of S. aureus based on Coagulase Fig. 2.
Fig. 3. Mechanism of phage=induced lysis of the bacteria: 
1 ) Phage detects specific receptors and adsorbs to them. 2) 
In the second step, the adsorbed phage injects its genome 
into the bacterial cytoplasm. 3) Host molecular machinery 
recognizes promoters on phage genome causing 
transcription and translation of protein products such 
as capsid and enzymes meanwhile the phage genome 
is replicated. 4) Assembly of completed phage particles, 
lysis of bacteria with holin  and exit out of the cell 
by diffusion. 5) Attach to new host and repeat cycle
Phage and genetic engineering
 Most gram-negative bacteria have 
extracellular lipopolysaccharide components that 
are often shared amongst different strains. Through 
the use of genetic engineering, we could modify the 
properties of a phage’s tail fibers that could allow 
it to bind to one or more ofthe shared components 
found in most lipopolysaccharide of gram-negative 
bacteria of interest resulting in a wider host range. 
In a study conducted by Lorena Rodríguez-Rubio 
three different proteins uses between lysostaphin 
and HydH5 resulted in increased performances 
of the 2 proteins compared to the wild type and 
caused lysis of the bacteria in plate and reduce the 
opaqueness of bacteria in liquid media29.
Phage therapy vs. Antibiotic therapy against 
MRSA
 The use of phage as an antimicrobial 
agent with similar efficacy to an antibiotic is one 
of the most exciting aspects in treating infections. A 
number of studies have shown the use of phage has 
no direct, negative effects on eukaryotic cells and 
the efficiency of phage can in some cases be greater 
than antibiotics. In addition, the problematic, 
disease-causing bacteria can be destroyed with 
no or minimal effect on neighboring and essential 
microbiotia. Smith et al. showed that a single 
intramuscular dose of one anti-K1 coliphage was 
more effective for treating mice challenged with 
E. coli intramuscularly than multiple intramuscular 
doses of Tetracycline, Chloramphenicol or 
Trimethoprim plus Sulfafurazole30. Chibani-
Chennouû et al. showed that all of the administered 
phage passed through the gastro in testinal tract 
in adult mice and destroyed a diarrheal E.coli 
strain31.Matsuzak et al. used four types of phage 
to treat 72  strainsof MRSA (Methicillin Resistance 
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Staphylococcus aureus) and showed that injections 
of 8*108 bacteria intra-peritoneal,caused bacteremia 
and eventual death in mice but when administration 
simultaneously with puriûed phage ØMR11 (MOI 
≥ 0.1) they suppressed S. aureus-induced lethality. 
High-doses of phage ØMR11 used on uninfected 
mice showed no adverse effects32. Miêdzybrodzki 
et al did a comparison between the cost of a phage 
therapy and antibiotic therapy and showed that 
the use of phage therapy in MRSA infections 
was less expensive to use than antibiotics such 
as Vancomycin,Linezolide, Teicoplanin and 
Chinupristin + Dalfopristin33. Clem attempted to 
use Staphphages to eliminate numerous MRSA 
strains and showed that many of their phages 
could not infect some of the strains and suggested 
a plausible phenomenon relating to the surface 
antigen properties such as clumping factor A, 
clumping factor B, Fibronectin Binding Protein A, 
Fibronectin Binding Protein B, collagen adhesion, 
SdrC, SdrD, SdrE, Protein A and Methicillin 
resistance surface proteins34.Gu et al used the phage 
endolysine(LysGH15) as a prophylactic to protect 
mice against the MRSA infections. Their results 
demonstrated that 50 µg of LysGH15 was sufficient 
to protect mice against injections at double the 
minimum lethal dose of MRSA when administered 
1 hour prior to the bacterial challenge35.S. 
O’Flaherty et al discovered and tested two 
novellytic phages (DW2 and CS1) against their 
entire personal collection of Staphylococci species 
that cause mastitis-associated infections and 
demonstrated their phages capabilities of being 
used as a prophylactic36. According to the above 
studies we concluded that the use the phage is often 
cheaper and promising for thetreatment of MRSA 
infections.Data shown in Table-1.
Problems with Phage therapy and possible 
solutions
A) Most phage have limit detection of the 
host, so that a narrow range of hosts ability 
to identify with phage.A possible solution 
could be to use polyvalent phages that can 
identify a wide range of bacteria37.
B) The presence of cellular debris and other 
by products from the host bacteria in phage 
preparations can cause negative immune 
responses. Using modern technology such 
as density gradient centrifugation can 
eliminate or greatly mitigate a patient’s 
exposure to these elements38.
C) Phage clear from the body rather fast if their 
host is not available,for more persistence 
can be used strains that delay detected and 
cleared by the immune system39.
CONCLUSION
 Numerous studies have used phage as 
an antimicrobial agent and have shown them to 
be effective at destroying target bacteria33, 40-43. 
Phage are highly specific and are only capable of 
lysing bacteria and have not been demonstrated to 
cause lysis or have direct negative immunological 
effects to eukaryotic cells44.Phages specificity is 
due to their tail fibers’ ability to bind to specific 
antigens on their host that aren’t present on other 
non-target bacteria. In other words the use of phage 
to attack problematic bacteria is beneficial and 
not likely to have any negative effects on normal 
microbiota; an effect often not seen in conventional 
broad-spectrum antibiotics. Another advantage 
of phage is that they can replicate at the site of 
infection and easily overcome and out number 
the bacteria after a number of infection cycles. 
The likelihood of a naturally occurring phage 
being able to infect a eukaryotic cell is highly 
unlikely and probably even impossible without 
the extensive use of genetic engineering in a lab 
setting. The receptors on the outer membrane of 
eukaryotes are significantly foreign in comparison 
to those of bacteria, the phage wouldn’t be able to 
penetrate the significantly thicker cell membrane, 
the inserted genome likely wouldn’t survive within 
the cytoplasm as well take over the molecular 
machinery of the host within the nuclei45.
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